Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL601317 | 0.84 | MAPT (0.36) | MAPTGAAALDH1A1 | |
| SCHEMBL600119 | 0.83 | MAPT (0.37) | MAPTRAB9AATMHPGDGAA | |
| SCHEMBL601778 | 0.81 | LMNA (0.33) | NCF1MAPTL3MBTL1HPGDTDP1 | |
| SCHEMBL600143 | 0.78 | ALDH1A1 (0.34) | MAPTL3MBTL1RAB9AHPGDTDP1 | |
| SCHEMBL600956 | 0.74 | MEN1 (0.33) | MAPT | |
| SCHEMBL600960 | 0.65 | GPR84 (0.39) | MAPTHPGDALDH1A1KDM4E | |
| SCHEMBL599561 | 0.64 | KDM4E (0.43) | MAPTATMHPGDGAAALDH1A1 | |
| SCHEMBL9386188 | 0.62 | ALDH1A1 (0.35) | NCF1MAPTL3MBTL1TDP1GAA | |
| SCHEMBL1685766 | 0.62 | L3MBTL1 (0.58) | MAPTL3MBTL1RAB9AHPGDTDP1 | |
| SCHEMBL20234907 | 0.61 | DRD2 (0.55) | L3MBTL1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2420500-A1 | PYRIDINE THIO DERIVATIVE, AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS SAME AND HAS ANTI-HELICOBACTER PYLORI ACTION | aRigen Pharmaceuticals, Inc. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120041030-A1 | PYRIDINE THIO DERIVATIVE, AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS SAME AND HAS ANTI-HELICOBACTER PYLORI ACTION | LINK GENOMICS, INC. (JP) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041030-A1 | PYRIDINE THIO DERIVATIVE, AND PHARMACEUTICAL COMPOSITION WHICH CONTAINS SAME AND HAS ANTI-HELICOBACTER PYLORI ACTION | TPMT, TST, PTPN11 | APOBEC3G 4790/4885NCF1 2067/4885MAPT 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.